Clinical trial
LIGHTBEAM-U01 Substudy 01B: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors
NCT06395090 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- LIGHTBEAM-U01 Substudy 01B: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 1/2
- Overall status
- Withdrawn
- Start date
- January 15, 2025
- Completion date
- June 30, 2029
- Enrollment
- 0 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.